TY - JOUR T1 - The impact of the COVID-19 pandemic on gastrointestinal infection trends in England, February – July 2020 JF - medRxiv DO - 10.1101/2021.04.06.21254174 SP - 2021.04.06.21254174 AU - Nicola K. Love AU - Alex J. Elliot AU - Rachel M Chalmers AU - Amy Douglas AU - Saheer Gharbia AU - Jacquelyn McCormick AU - Helen Hughes AU - Roger Morbey AU - Isabel Oliver AU - Roberto Vivancos AU - Gillian Smith Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/08/2021.04.06.21254174.abstract N2 - Objective To establish the impact of the first six months of the COVID-19 outbreak response of gastrointestinal (GI) infection trends in England.Design Retrospective ecological study using routinely collected national and regional surveillance data from eight Public Health England coordinated laboratory, outbreak and syndromic surveillance systems using key dates of UK governmental policy change to assign phases for comparison between 2020 and historic data.Results Decreases in GI illness activity were observed across all surveillance indicators as COVID-19 cases began to peak. Compared to the 5-year average (2015-2019), during the first six months of the COVD-19 response, there was a 52% decrease in GI outbreaks reported (1,544 vs. 3,208 (95% CI: 2,938 – 3,478) and a 34% decrease in laboratory confirmed cases (27,859 vs. 42,495 (95% CI: 40,068 – 44,922). GI indicators began to rise during the first lockdown and lockdown easing, although all remained substantially lower than historic figures. Reductions in laboratory confirmed cases were observed across all age groups and both sexes, with geographical heterogeneity observed in diagnosis trends. Health seeking behaviour changed substantially, with attendances decreasing prior to lockdown across all indicators.Conclusions There has been a marked change in trends of GI infections in the context of the COVID-19 pandemic. The drivers of this change are likely to be multifactorial; while changes in health seeking behaviour, pressure on diagnostic services and surveillance system ascertainment have undoubtably played a role there has likely been a true decrease in the incidence for some pathogens resulting from the control measures and restrictions implemented. This suggests that if some of these changes in behaviour such as improved hand hygiene were maintained, then we could potentially see sustained reductions in the burden of GI illness.Strengths and limitations of this studyOur findings show that there has been a marked change in the burden of GI infections during the COVID-19 outbreak, and although undoubtably changes to health care and surveillance ascertainment have played a role, there does appear to be a true decrease in incidence. These findings suggest that if effective implementation of infection control measures were maintained, then we could see sustained reductions in the person to person transmission of GI illness in England.This study was strengthened by the triangulation of data from several national and regional-based surveillance systems; using this approach we could determine that the trends observed were consistent across all indicators.It has not been possible to definitively differentiate the relative contributions of the reduced ascertainment of GI infections versus a true decrease in GI disease burden in this study, which an additional focussed analysis could address.This analysis includes only the first six-months of the COVID-19 outbreak response, and further longitudinal analyses will be performed to explore this further and assess any change as we move into further phases of the pandemicCompeting Interest StatementThe authors have declared no competing interest.Funding StatementAJE, RV, HH, and GES receive support from the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections, IO receives support from the NIHR HPRU in Behavioural Science and Evaluation. GES, RM and AJE receive support from the NIHR HPRU in Emergency Preparedness and Response. The views expressed are those of the author(s) and not necessarily those of the NIHR, Public Health England or the Department of Health and Social Care. Funding was not applicable to this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted under the provisions of Section 251 of the NHS Act 2006 and therefore did not require individual patient consent. The study was reviewed by the PHE Research Ethics and Governance Group and was found to be fully compliant with all regulatory requirements. As no regulatory or ethical issues were identified the study was approved.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo additional data available ER -